Antibody-drug conjugates (ADCs): all 1,111 studies that test it
Page 5 of 12. Open to participants first (502), then studies with results posted, then the rest; newest registration first within each.
- Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple MyelomaRecruitingNCT05789303Phase 2
- Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial CancerRecruitingNCT05775471Phase 2
- Circulating Tumor DNA to Guide Changes in Standard of Care ChemotherapyRecruitingNCT05770531Phase 2
- Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant HistologyRecruitingNCT05756569Phase 2
- A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALLRecruitingNCT05748171Phase 2
- A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 MutationNot yet recruitingNCT05745740Phase 1/2
- Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial CarcinomaRecruitingNCT05723991Phase 4
- A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination TreatmentsRecruitingNCT05714839Phase 1/2
- NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast CancerRecruitingNCT05704829Phase 2
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingNCT05675410Phase 3
- A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)RecruitingNCT05673928Phase 2
- Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaRecruitingNCT05672251Phase 2
- Renal Retention in High Grade Upper Tract Urothelial CancerRecruitingNCT05656235Phase 2
- Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaRecruitingNCT05645718Phase 2
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)RecruitingNCT05633654Phase 3
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT05633615Phase 2
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerRecruitingNCT05601440Phase 2
- Treatment Strategy for Relapsed/Refractory Hodgkin LymphomaRecruitingNCT05595447Phase 2/3
- CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AMLRecruitingNCT05558124Phase 1
- Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal CancerRecruitingNCT05493683Phase 2
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)RecruitingNCT05489211Phase 2
- A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial CarcinomaNot yet recruitingNCT05488353Phase 4
- A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell TherapyRecruitingNCT05464719Phase 2
- RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2Not yet recruitingNCT05417230Phase 2
- Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersRecruitingNCT05408845Phase 2
- RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2RecruitingNCT05403242Phase 1/2
- Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 GeneRecruitingNCT05372614Phase 1
- Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis FungoidesRecruitingNCT05357794Phase 2
- An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder CancerNot yet recruitingNCT05356351Phase 2
- SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.RecruitingNCT05351788Phase 2
- Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal CancerNot yet recruitingNCT05333809Phase 2
- Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)RecruitingNCT05332561Phase 2
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)RecruitingNCT05319730Phase 1/2
- Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell LymphomaRecruitingNCT05313243Phase 2
- A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial CarcinomaRecruitingNCT05302284Phase 3
- A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder CancerRecruitingNCT05297552Phase 2
- Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone LymphomaRecruitingNCT05296070Phase 2
- Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast CancerRecruitingNCT05288777Phase 2/3
- Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer PatientsRecruitingNCT05274048Phase 1
- Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's LymphomaRecruitingNCT05243693Phase 2
- A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) CancerNot yet recruitingNCT05241899Phase 2
- Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk MyelomaRecruitingNCT05208307Phase 2
- Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin LymphomaRecruitingNCT05180097Phase 2
- Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL AmyloidosisRecruitingNCT05145816Phase 1/2
- A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)RecruitingNCT05135715Phase 2
- RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast CancerNot yet recruitingNCT05134519Phase 2
- Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT05091372Phase 2
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingNCT05061550Phase 2
- A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple MyelomaRecruitingNCT05055063Phase 1
- Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint InhibitorsRecruitingNCT05039073Phase 2
- Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular LymphomaRecruitingNCT04998669Phase 2
- Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast CancerRecruitingNCT04965766Phase 2
- A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological MalignanciesRecruitingNCT04965519Phase 2
- A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT04928846Phase 3
- Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCLNot yet recruitingNCT04913103Phase 2
- ATEMPT 2.0: Adjuvant T-DM1 vs THRecruitingNCT04893109Phase 2
- A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2RecruitingNCT04879329Phase 2
- Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple MyelomaRecruitingNCT04822337Phase 1/2
- Treatment Study for Children and Adolescents With Acute Promyelocytic LeukemiaRecruitingNCT04793919Phase 2
- Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)RecruitingNCT04747912Phase 2
- PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyRecruitingNCT04745949Phase 2
- Sacituzumab Govitecan Plus EV in Metastatic UCRecruitingNCT04724018Phase 1/2
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionRecruitingNCT04714190Phase 3
- Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLCRecruitingNCT04686305Phase 1
- Brentuximab Vedotin in Early Stage Hodgkin LymphomaRecruitingNCT04685616Phase 3
- Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular DysfunctionRecruitingNCT04680442Phase 2
- Post-op T-DM1 in HER-2+ Salivary Gland CarcinomasRecruitingNCT04620187Phase 2
- Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver ImpairmentRecruitingNCT04617522Phase 1
- Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell TumorRecruitingNCT04616560Phase 2
- Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal CancerRecruitingNCT04606914Phase 2
- Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular LymphomaRecruitingNCT04587687Phase 2
- Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian CancerRecruitingNCT04585958Phase 1
- Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin LymphomaRecruitingNCT04561206Phase 2
- Sacituzumab Govitecan in Recurrent GlioblastomaRecruitingNCT04559230Phase 2
- Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast CancerRecruitingNCT04553770Phase 2
- Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin LymphomaRecruitingNCT04491370Phase 1/2
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingNCT04486352Phase 1/2
- Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)RecruitingNCT04434040Phase 2
- A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2RecruitingNCT04400695Phase 3
- Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)RecruitingNCT04385290Phase 1/2
- BREntuximab Vedotin in SEcond LIne Therapy BEfore TransplantRecruitingNCT04378647Phase 2
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingNCT04341181Phase 2
- Sacituzumab Govitecan In TNBCRecruitingNCT04230109Phase 2
- Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AMLRecruitingNCT04168502Phase 3
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)RecruitingNCT04165070Phase 1/2
- CLAG-GO for Patients With Persistent, Relapsed or Refractory AMLRecruitingNCT04050280Phase 2
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyRecruitingNCT03959085Phase 3
- Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial CancerRecruitingNCT03832361Phase 2
- Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic LeukemiaRecruitingNCT03739814Phase 2
- Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid LeukemiaRecruitingNCT03737955Phase 2
- Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/LymphomaRecruitingNCT03719105Early Phase 1
- Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALLRecruitingNCT03460522Phase 2
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingNCT03424005Phase 1/2
- Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First RelapseRecruitingNCT03356054Phase 1/2
- Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaRecruitingNCT03150693Phase 3
- Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic LeukemiaRecruitingNCT03104491Phase 1/2
- Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic LeukemiaRecruitingNCT02877303Phase 2
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2
- Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic LeukemiaRecruitingNCT01409161Phase 2
- Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic LeukemiaRecruitingNCT01371630Phase 1/2